Eversept Partners LP Takes $630,000 Position in Whitehawk Therapeutics, Inc. $WHWK

Eversept Partners LP purchased a new stake in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 260,259 shares of the company’s stock, valued at approximately $630,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. acquired a new stake in shares of Whitehawk Therapeutics during the third quarter valued at about $2,552,000. Peapod Lane Capital LLC purchased a new position in Whitehawk Therapeutics in the third quarter valued at $577,000. Dimensional Fund Advisors LP purchased a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $84,000. Avoro Capital Advisors LLC purchased a new position in Whitehawk Therapeutics in the third quarter worth approximately $5,414,000. Finally, Suvretta Capital Management LLC acquired a new position in shares of Whitehawk Therapeutics during the third quarter worth $7,030,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Whitehawk Therapeutics

In other Whitehawk Therapeutics news, CFO Scott M. Giacobello sold 141,600 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $4.13, for a total transaction of $584,808.00. Following the completion of the transaction, the chief financial officer directly owned 295,224 shares in the company, valued at approximately $1,219,275.12. This trade represents a 32.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David James Lennon sold 14,500 shares of Whitehawk Therapeutics stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $3.38, for a total transaction of $49,010.00. Following the transaction, the chief executive officer owned 518,622 shares of the company’s stock, valued at approximately $1,752,942.36. The trade was a 2.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 695,830 shares of company stock valued at $2,553,026. Insiders own 49.90% of the company’s stock.

Whitehawk Therapeutics Price Performance

Shares of NASDAQ:WHWK opened at $4.22 on Thursday. The firm has a market capitalization of $208.68 million, a price-to-earnings ratio of -2.51 and a beta of 0.77. The business’s 50 day simple moving average is $4.18 and its 200-day simple moving average is $3.39. Whitehawk Therapeutics, Inc. has a 12 month low of $1.57 and a 12 month high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.04. On average, equities analysts anticipate that Whitehawk Therapeutics, Inc. will post -1.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on WHWK. Weiss Ratings downgraded Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, June 5th. Citigroup started coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They issued an “outperform” rating on the stock. Oppenheimer restated an “outperform” rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Wall Street Zen cut Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Citizens Jmp started coverage on shares of Whitehawk Therapeutics in a research report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.33.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.